In Tau35 mice, progressive defects in synaptic connectivity and ultrastructure occur alongside functional abnormalities in HCN channel activity and network dynamics, suggesting that pharmacological targeting of specific HCN channels could have significant therapeutic potential in human tauopathy. The gene discussed is MALAT1; the disease is tauopathy.